These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 39117488)
1. A Phase I Dose-Escalation Study of The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Polyethylene Glycol-Erythropoietin (PEG-EPO) in Healthy Subjects. Hu C; Sun W; Wu Y; Huang J; Zhang X; Zhang L Clin Ther; 2024 Aug; 46(8):636-643. PubMed ID: 39117488 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis. Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140 [TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study. Yang L; Fang Y; Luo Y; Fu M; Shen K; Luo Z Expert Opin Investig Drugs; 2024 Jul; 33(7):741-752. PubMed ID: 38805242 [TBL] [Abstract][Full Text] [Related]
5. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon Yoon S; Rhee SJ; Heo SJ; Oh TY; Yoon SH; Cho JY; Lee S; Yu KS Drug Des Devel Ther; 2017; 11():3127-3135. PubMed ID: 29138535 [TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Ma XZ; Xia YH; Tian JH; Ma Y; Liu Y; Zhang P; Xu M Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):265-275. PubMed ID: 33576936 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217 [TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637 [TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study. Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838 [TBL] [Abstract][Full Text] [Related]
12. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. Donck J; Gonzalez-Tabares L; Chanliau J; Martin H; Stamatelou K; Manamley N; Farouk M; Addison J Adv Ther; 2014 Nov; 31(11):1155-68. PubMed ID: 25367412 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial. Yang L; Shu P; Wu N; Hu M; Luo Z Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064 [TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects. Li K; Dong L; Gao S; Zhang J; Feng Y; Gu L; Yang J; Liu X; Wang Y; Mao Z; Jiang D; Xia Z; Zhang G; Tang J; Ma P; Zhang W Eur J Pharm Sci; 2024 Apr; 195():106723. PubMed ID: 38336251 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers. Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent. Han H; Lee J; Shin D; Shin KH; Jeon H; Lim KS; Yoon SH; Shin SG; Jang IJ; Cho JY; Yu KS Clin Drug Investig; 2014 Jun; 34(6):373-82. PubMed ID: 24623104 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547 [TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study. Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285 [TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766 [TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects. Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]